{"id":"W2954564366","doi":"10.1200/jco.2019.37.15_suppl.7058","title":"Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Monocytosis; Myelofibrosis; Discontinuation; Interleukin-3 receptor; Phases of clinical research; Gastroenterology; Anagrelide; Clinical trial; Oncology; Leukemia; Bone marrow; Platelet; Essential thrombocythemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002201803,0.001310054,0.001456938,0.0002680422,0.0003713614,0.0007448682,0.0006653506,0.001512786,0.005780139],"category_scores_gemma":[0.001032528,0.0003789157,0.0009716054,0.000232558,0.0004975568,0.0007964513,0.0002512301,0.002169828,0.001202535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006559351,"about_ca_system_score_gemma":0.00116307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009480015,"about_ca_topic_score_gemma":0.002533903,"domain_scores_codex":[0.9996258,0.0001891371,0.00002319707,0.00004850743,0.00003817088,0.00007515163],"domain_scores_gemma":[0.9992608,0.0001575849,0.000134177,0.00005042845,0.00005641899,0.0003404945],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7564285,0.04201299,0.01093863,0.001127908,0.001787301,0.0004631973,0.0002532926,0.002798171,0.03217399,0.0003484561,0.01713863,0.1345289],"study_design_scores_gemma":[0.6626398,0.2994049,0.02742541,0.0001029697,0.0007381209,0.000516616,0.00004883846,0.001064928,0.002385128,0.000320097,0.005320838,0.00003244543],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9709588,0.00503421,0.001163928,0.001785555,0.0002388714,0.006259487,0.007995716,0.000263331,0.006300134],"genre_scores_gemma":[0.9614813,0.003327969,0.003688967,0.00296011,0.0002982797,0.006340839,0.0165176,0.00005067877,0.005334272],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005780139,"threshold_uncertainty_score":0.01933646,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08061642482235527,"score_gpt":0.4386688767717317,"score_spread":0.3580524519493764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}